Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) EBIT (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed EBIT for 11 consecutive years, with -$57.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT rose 6.66% year-over-year to -$57.2 million, compared with a TTM value of -$209.6 million through Dec 2025, changed 0.48%, and an annual FY2025 reading of -$209.6 million, changed 0.48% over the prior year.
  • EBIT was -$57.2 million for Q4 2025 at Spyre Therapeutics, roughly flat from -$56.9 million in the prior quarter.
  • Across five years, EBIT topped out at -$6.7 million in Q2 2021 and bottomed at -$159.2 million in Q2 2023.
  • Average EBIT over 5 years is -$40.5 million, with a median of -$33.2 million recorded in 2022.
  • The sharpest move saw EBIT crashed 610.19% in 2023, then soared 72.28% in 2024.
  • Year by year, EBIT stood at -$20.4 million in 2021, then rose by 6.26% to -$19.2 million in 2022, then plummeted by 139.61% to -$45.9 million in 2023, then plummeted by 33.41% to -$61.3 million in 2024, then increased by 6.66% to -$57.2 million in 2025.
  • Business Quant data shows EBIT for SYRE at -$57.2 million in Q4 2025, -$56.9 million in Q3 2025, and -$41.9 million in Q2 2025.